NexMed (NEXM) Murdered After Pulling NDA for NM100060
Tweet
Share
E-mailGet Alerts NEXM Hot Sheet
Join SI Premium – FREE
Shares of NexMed, Inc. (Nasdaq: NEXM) are under heavy pressure this morning (-76%) following news the company will not to submit a New Drug Application for NM100060 with the FDA at this time.
NexMed cited the First Interpretable Results of Phase III clinical studies for NM100060, which is a topical application of terbinafine formulated with NexACT for the treatment of onychomycosis.
CEO Vivian Liu said, "While this is disappointing, a European comparator study is still ongoing, and those results are expected mid 2009."
NexMed cited the First Interpretable Results of Phase III clinical studies for NM100060, which is a topical application of terbinafine formulated with NexACT for the treatment of onychomycosis.
CEO Vivian Liu said, "While this is disappointing, a European comparator study is still ongoing, and those results are expected mid 2009."
You May Also Be Interested In
- Trump says to rename Lake Ontario to Lake America
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Hunterbrook Capital is short bonds issued by Sammons Financial Group and short Guggenheim Strategic Opportunities Fund
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
